article thumbnail

Opinion: Pharma’s ethically questionable sites essentially sell drugs directly to consumers

STAT

Some of the largest pharmaceutical companies in the U.S. This unprecedented move launches a new dystopic era: pharmaceutical companies as health care provider, no pesky physician middlemen needed. Want to self-prescribe a prescription drug? No problem!

article thumbnail

STAT+: FDA tells drugmakers to redo studies run by a contract research firm due to data integrity issues

STAT

During an April 2023 inspection at Raptim facilites in Nava Mumbai, India, FDA inspectors found “objectionable conditions” that led them to conclude the company falsified data in testing for multiple subjects and samples across multiple studies, according to a letter sent last week to the pharmaceutical companies.

FDA 136
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Wyden claims Pfizer used a ‘colossal’ scheme to avoid paying billions in U.S. taxes

STAT

lawmaker described as possibly the “largest tax-dodging scheme” by a pharmaceutical company in history, Pfizer sold $20 billion in medicines to U.S. In what one U.S.

article thumbnail

Which Social Media Analytics Matter Most in Pharma Marketing

Pharma Marketing Network

Unlike traditional consumer brands, pharmaceutical companies face unique challenges on social media, including strict regulations, compliance concerns, and the need for factual accuracy. For pharmaceutical companies, this can provide insights into public perception of drug launches, patient experiences, and industry discussions.

HIPAA 52
article thumbnail

Opinion: How to stop the shift of drug discovery from the U.S. to China

STAT

pharmaceutical companies didn’t license any new drugs from China. Five years ago, U.S. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China?

article thumbnail

STAT+: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent

STAT

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay $16.5 billion for Catalent, a leading contract drug manufacturer.

article thumbnail

STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

STAT

Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result.